Telomir Pharmaceuticals Inc. Common Stock

TELO | NASDAQ

$1.25

+$0.01 (+0.81%)

Sep 22, 2026, 1:09 PM ET · Market open

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021
Net Income	-10.41M	-16.53M	-13.07M	-854.15K	-138.13K
Depreciation & Amortization	n/a	4.34M	n/a	n/a	n/a
Stock-Based Compensation	5.29M	6.87M	n/a	n/a	n/a
Other Working Capital	645.46K	-57.16K	-713	385.49K	18.74K
Other Non-Cash Items	840K	130K	9.1M	n/a	n/a
Deferred Income Tax	n/a	n/a	n/a	n/a	n/a
Change in Working Capital	594.69K	126.47K	113.84K	385.49K	18.74K
Operating Cash Flow	-3.69M	-5.07M	-3.86M	-468.66K	-119.4K
Capital Expenditures	n/a	n/a	-4	n/a	n/a
Cash Acquisitions	n/a	n/a	n/a	n/a	n/a
Purchase of Investments	n/a	n/a	n/a	n/a	n/a
Sales Maturities Of Investments	n/a	n/a	n/a	n/a	n/a
Other Investing Acitivies	n/a	n/a	n/a	n/a	n/a
Investing Cash Flow	n/a	n/a	n/a	n/a	n/a
Debt Repayment	n/a	-101K	3.17M	462.39K	n/a
Common Stock Repurchased	n/a	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	155.52K	-396.65K	-310.38K	7.69K	119.4K
Financial Cash Flow	9.71M	6.34M	3.86M	470.08K	119.4K
Net Cash Flow	6.02M	1.26M	-188	1.42K	n/a
Free Cash Flow	-3.69M	-5.07M	-3.86M	-468.66K	-119.4K
Adj. Free Cash Flow	-8.98M	-11.94M	-3.86M	-468.66K	-119.4K
Maintenance CapEx	n/a	n/a	n/a	n/a	n/a
Growth CapEx	n/a	n/a	-4	n/a	n/a
Owner Earnings	-3.69M	-5.07M	-3.86M	-468.66K	-119.4K